HLG Genomics stocks fell 4.65% on their first trading day on KOSDAQ on the 24th, dropping to 20,500 won compared to the IPO price of 21,500 won as of 10:21 AM. The decline occurred despite the company attracting over 4 trillion won in subscription deposits during its initial public offering. The stock weakness stemmed from institutional investors' reluctance toward long-term holdings, with only 1.9% of participating institutions committing to mandatory lock-up agreements, allowing the remaining 98.1% to sell shares immediately upon listing.
HLG Genomics Opens at 25,500 Won Before Reversing to Losses
HLG Genomics began trading at 25,500 won, 1.2 times the IPO price of 21,500 won, immediately after market opening. The stock maintained gains of 4% in early trading before the upward momentum weakened to 1-2% range. The stock then reversed course and fell below the IPO price.
HLG Genomics Records 667.23:1 Subscription Competition Ratio
The active pharmaceutical ingredient (API) manufacturer achieved partial success during its IPO process. During the book-building period conducted from the 2nd to 8th of this month, 98.5% of participating institutions submitted bids at or above the upper band of the indicative price range of 18,500-21,500 won. The IPO price was confirmed at 21,500 won based on this demand. The general public subscription attracted a competition ratio of 667.23:1, collecting approximately 4.6 trillion won in subscription deposits.
Institutional Investors Commit Only 1.9% to Lock-Up Agreements
Institutional investors demonstrated low commitment to long-term investment. Among institutions participating in book-building, the mandatory lock-up commitment ratio reached only 1.9% based on requested quantities. Of the total 1.374549 billion shares submitted, 98.1% or 1.348308 billion shares carried no lock-up commitments. Institutions that did not pledge long-term holdings released their shares into the market from the first trading day, contributing to downward pressure on the stock price.
HLG Genomics Allocates 55.1 Billion Won for Factory Expansion
HLG Genomics secured approximately 55.1 billion won through the IPO. The company plans to invest the funds in expanding its second factory to strengthen supply stability for its existing API business, while expanding its foundation in new businesses including vaccine microneedle operations.
FAQ
What was HLG Genomics' stock price performance on its first trading day?
HLG Genomics stocks fell 4.65% on the 24th, trading at 20,500 won compared to the IPO price of 21,500 won as of 10:21 AM. The stock opened at 25,500 won before reversing to losses.
Why did HLG Genomics stocks decline despite strong IPO demand?
The stock decline occurred because only 1.9% of institutional investors committed to mandatory lock-up agreements during book-building. The remaining 98.1% of institutional holdings, representing 1.348308 billion shares, carried no lock-up commitments, allowing immediate selling pressure from the first trading day.
How much funding did HLG Genomics raise through its IPO?
HLG Genomics secured approximately 55.1 billion won through the IPO. The company plans to invest the funds in expanding its second factory and developing new businesses including vaccine microneedle operations.
